News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in Medicine
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Asembia 2025 |
Sales Effectiveness|
Latest Executive Roundtables
Advertisement

Milana Chamberlain and George Cameron

Advertisement

Articles by Milana Chamberlain and George Cameron

Human Rights on the Pharma Risk Management Agenda

ByMilan Chamberlain and George Cameron,Milana Chamberlain and George Cameron
November 3rd 2016

Milana Chamberlain and George Cameron ask: is it time for pharma to start using human rights language?

Advertisement

Latest Updated Articles

  • Human Rights on the Pharma Risk Management Agenda
    Human Rights on the Pharma Risk Management Agenda

    Published: November 3rd 2016 | Updated:



Advertisement
Advertisement

Trending on PharmExec

1

TrumpRx and the Dawn of Direct-to-Consumer Commercialization

2

Could DTC Programs Help Simplify the Drug-Pricing System?

3

Lilly Enters Definitive Agreement Acquiring Aderum Biotechnologies

4

AI Becomes Pharma’s New Operating System: Q&A with causaLens’ CEO and Co-Founder Darko Matovski

5

FDA Approves Blenrep for Treatment of Replapsed/Refractory Multiple Myeloma

  • About
  • Advertise
  • Contact Us
  • Editorial Board
  • Editorial Submission Guidelines
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us